CN Patent

CN1342090A — 适用于心血管疾病的回肠胆汁酸转运抑制剂和贝酸衍生物的组合

Assigned to GD Searle LLC · Expires 2002-03-27 · 24y expired

What this patent protects

本发明提供预防或治疗心血管疾病包括高胆固醇血症、动脉粥样硬化或高脂血症的心血管的治疗性化合物的组合。所公开的组合包括与贝酸衍生物联合的回肠胆汁酸转运抑制剂。

USPTO Abstract

本发明提供预防或治疗心血管疾病包括高胆固醇血症、动脉粥样硬化或高脂血症的心血管的治疗性化合物的组合。所公开的组合包括与贝酸衍生物联合的回肠胆汁酸转运抑制剂。

Drugs covered by this patent

maralixibat-chloride (MARALIXIBAT CHLORIDE)

Patent Metadata

Patent number: CN1342090A
Jurisdiction: CN
Classification: —
Expires: 2002-03-27
Drug substance claim: No
Drug product claim: No
Assignee: GD Searle LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.